Former OpenAI science lead Kevin Weil launches AI drug discovery startup with $215 million funding

Former OpenAI science lead Kevin Weil launches AI drug discovery startup with $215 million funding

N
News Editor
2026-10-22 15:37:06
Kevin Weil, a former science leader at OpenAI, has started a new company focused on using artificial intelligence to speed up key stages of drug development. According to Bloomberg, the startup has already raised $215 million. Weil previously worked at OpenAI on applications of AI in scientific research, linking his new venture to his earlier work in the field. The brief announcement did not disclose the company’s name, investors, or a more detailed product roadmap, but it identified drug research acceleration as the core objective. The funding size places the launch among the larger early financing rounds tied to AI-driven science and biotech efforts.

Kevin Weil, a former science executive at OpenAI, has launched a new startup aimed at using artificial intelligence to accelerate key steps in drug development.

According to Bloomberg, the company has raised $215 million. Weil previously worked at OpenAI on AI applications for science.

This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan.
6800

Disclaimer:

The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.

Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.

Former OpenAI science lead Kevin Weil launches AI drug discovery startup with $215 million funding | Bit.Fan